Borrui Pharmaceuticals

Borui Biopharma is a leading Chinese biopharmaceutical company specializing in the development and manufacture of high-barrier generic drugs and innovative therapeutics. The company focuses on complex small molecules, fermentation-based drugs, and peptide-based medicines across therapeutic areas such as oncology, infectious diseases, and metabolic disorders. Borui is notably advancing a pipeline of innovative drugs, including multi-target GLP-1 receptor agonists for diabetes and obesity, as well as drug conjugates for cancer treatment. With integrated R&D and GMP-compliant manufacturing capabilities, the company serves both domestic and international markets through its own products and CDMO services. The firm is listed on the Shanghai Stock Exchange STAR Market and maintains a strong reputation for technical excellence in chemical synthesis and fermentation.